VistaGen reports Phase 3 fasedienol shows positive efficacy signal in severe social anxiety subgroup analysis

Reuters2026/09/10 12:31

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

VistaGen set a Psych Congress 2026 poster for Sept. 17-18 in New Orleans on Phase 3 fasedienol nasal spray data.
Results have not been presented yet; the company plans to disclose subgroup analyses at the meeting.
Data highlight a positive efficacy signal in public speaking challenge participants with very severe social anxiety disorder.
Readout targets acute treatment positioning, supporting the investment case for its lead intranasal pherine program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100830PRIMZONEFULLFEED9824302) on September 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

VistaGen reports Phase 3 fasedienol shows positive efficacy signal in severe social anxiety subgroup analysis

You may also like

Crypto prices